Endogenous glutamine is rate-limiting for anti-CD3 and anti-CD28 induced CD4+ T-cell proliferation and glycolytic activity under hypoxia and normoxia.
Saved in:
| Title: | Endogenous glutamine is rate-limiting for anti-CD3 and anti-CD28 induced CD4+ T-cell proliferation and glycolytic activity under hypoxia and normoxia. |
|---|---|
| Authors: | Wik JA; Division of Molecular Nutrition, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.; Department of Pathology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Chowdhury A; Division of Molecular Nutrition, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., Kolan S; Division of Molecular Nutrition, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., Bastani NE; Division of Molecular Nutrition, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., Li G; Division of Molecular Nutrition, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., Alam K; Division of Molecular Nutrition, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., Grimolizzi F; Division of Molecular Nutrition, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., Skålhegg BS; Division of Molecular Nutrition, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. |
| Source: | The Biochemical journal [Biochem J] 2022 Jun 17; Vol. 479 (11), pp. 1221-1235. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Published by Portland Press on behalf of the Biochemical Society Country of Publication: England NLM ID: 2984726R Publication Model: Print Cited Medium: Internet ISSN: 1470-8728 (Electronic) Linking ISSN: 02646021 NLM ISO Abbreviation: Biochem J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
